The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer

Latest advances in non-small cell lung cancer (NSCLC) therapies have revolutionized the treatment regimens utilized for NSCLCs with or without a driver mutation. Molecular targeted treatments such as tyrosine kinase inhibitors (TKIs) are utilized to prevent tumor progression and improve survival. De...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalra, Anjali, Rashdan, Sawsan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140561/
https://www.ncbi.nlm.nih.gov/pubmed/37124513
http://dx.doi.org/10.3389/fonc.2023.1158417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140561/
https://www.ncbi.nlm.nih.gov/pubmed/37124513
http://dx.doi.org/10.3389/fonc.2023.1158417

Ejemplares similares